8-K: Revvity Reports Mixed Q1 2024 Results, Reaffirms Full-Year Guidance

Revvity's first quarter results show a revenue of $650 million with a slight decrease in growth, but the company reaffirms its full-year guidance.

Summary

• Revvity announced its financial results for the first quarter of 2024, reporting a revenue of $650 million.
• This represents a 4% decrease in reported revenue and a 3% decrease in organic revenue compared to the same period last year.
• GAAP earnings per share (EPS) were $0.21, significantly lower than the $4.50 reported in the first quarter of 2023.
• Adjusted EPS from continuing operations was $0.98, down from $1.01 in the prior year.
• The company's GAAP operating income from continuing operations was $44 million, a decrease from $76 million year-over-year.
• The Life Sciences segment saw an 8% decrease in both reported and organic revenue, while the Diagnostics segment's reported revenue was flat, with a 1% increase in organic revenue.
• Revvity has updated its full-year 2024 total revenue guidance to a range of $2.76-$2.82 billion, reflecting changes in foreign currency exchange rates.
• The company reaffirmed its full-year adjusted EPS guidance of $4.55-$4.75 and organic growth guidance of 1-3%.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative due to the mixed results. While the company reaffirms its full-year guidance, the significant drop in GAAP EPS and revenue decline in the Life Sciences segment are concerning. The reaffirmation of guidance and positive comments from management provide some optimism, but the overall tone is cautious.

Positives

• The Diagnostics segment showed resilience with flat reported revenue and a 1% increase in organic revenue.
• Revvity reaffirmed its full-year 2024 adjusted EPS and organic growth guidance, indicating confidence in future performance.
• The company highlighted progress on strategic priorities and bringing cutting-edge innovations to market.

Negatives

• Revvity experienced a 4% decrease in reported revenue and a 3% decrease in organic revenue in Q1 2024.
• GAAP EPS significantly decreased to $0.21 from $4.50 in the same period last year.
• Adjusted EPS from continuing operations also declined to $0.98 from $1.01 year-over-year.
• The Life Sciences segment saw a notable 8% decrease in both reported and organic revenue.
• GAAP operating income from continuing operations decreased to $44 million from $76 million year-over-year.
• The company's GAAP operating profit margin from continuing operations decreased to 6.8% from 11.3% in the same period last year.

Risks

• The company faces risks related to market declines, global economic and political fluctuations, and the ability to introduce new products in a timely manner.
• There are risks associated with executing acquisitions and divestitures, integrating acquired businesses, and competing effectively.
• Disruptions in supply chains, IT systems, and the loss of key personnel are also potential risks.
• The company is exposed to risks related to product liability claims, compliance with government regulations, and data privacy laws.
• Economic and political risks associated with foreign operations and the ability to obtain future financing are also noted.

Future Outlook

Revvity has updated its full-year 2024 total revenue guidance to a range of $2.76-$2.82 billion and reaffirmed its adjusted EPS guidance of $4.55-$4.75 and organic growth guidance of 1-3%.

Management Comments

• Prahlad Singh, president and chief executive officer of Revvity, stated that the company made significant progress on strategic priorities during the first few months of the year.
• He also mentioned bringing cutting-edge innovations to market and optimizing the business during a period of industry adjustment.
• Management believes the improvements made position the company well for differentiated performance in the coming years.

Industry Context

The results reflect a period of industry adjustment, with some segments experiencing revenue declines while others show resilience. The company's focus on innovation and strategic optimization suggests an attempt to navigate current market challenges and position itself for future growth.

Comparison to Industry Standards

• Revvity's performance in Q1 2024, with a 3% organic revenue decline, contrasts with some of its peers in the life sciences and diagnostics sectors, which have shown varied results.
• For example, companies like Thermo Fisher Scientific and Danaher have reported different growth trajectories, with some experiencing stronger growth in certain segments.
• The diagnostics sector has seen mixed performance, with some companies benefiting from increased testing volumes while others face pricing pressures.
• Revvity's adjusted operating profit margin of 25.5% is within the range of some industry peers, but lower than others, indicating a need for further operational improvements.
• The company's reaffirmation of full-year guidance suggests confidence in its ability to meet targets despite the challenging start to the year.

Stakeholder Impact

• Shareholders may be concerned about the decrease in earnings per share and revenue.
• Employees may be affected by the company's restructuring and optimization efforts.
• Customers may benefit from the company's focus on bringing cutting-edge innovations to market.
• Suppliers may be impacted by changes in the company's supply chain and procurement strategies.
• Creditors will be monitoring the company's financial performance and ability to meet its debt obligations.

Next Steps

• The company will discuss its first quarter 2024 results and its outlook for business trends during a webcast on April 29, 2024, at 8:00 a.m. Eastern Time.

Key Dates

Keywords

financial results, revenue, earnings per share, EPS, organic growth, Life Sciences, Diagnostics, guidance, operating income, profit margin